Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

Blood
Warren FiskusKapil Bhalla

Abstract

AMN107 (Novartis Pharmaceuticals, Basel, Switzerland) has potent in vitro and in vivo activity against the unmutated and most common mutant forms of Bcr-Abl. Treatment with the histone deacetylase inhibitor LBH589 (Novartis) depletes Bcr-Abl levels. We determined the effects of AMN107 and/or LBH589 in Bcr-Abl-expressing human K562 and LAMA-84 cells, as well as in primary chronic myelogenous leukemia (CML) cells. AMN107 was more potent than imatinib mesylate (IM) in inhibiting Bcr-Abl tyrosine kinase (TK) activity and attenuating p-STAT5, p-AKT, Bcl-x(L), and c-Myc levels in K562 and LAMA-84 cells. Cotreatment with LBH589 and AMN107 exerted synergistic apoptotic effects with more attenuation of p-STAT5, p-ERK1/2, c-Myc, and Bcl-x(L) and increases in p27 and Bim levels. LBH589 attenuated Bcr-Abl levels and induced apoptosis of mouse pro-B BaF3 cells containing ectopic expression of Bcr-Abl or the IM-resistant, point-mutant Bcr-AblT315I and Bcr-AblE255K. Treatment with LBH589 also depleted Bcr-Abl levels and induced apoptosis of IM-resistant primary human CML cells, including those with expression of Bcr-AblT315I. As compared with either agent alone, cotreatment with AMN107 and LBH589 induced more loss of cell viability of primary...Continue Reading

References

May 9, 1998·Genes & Development·J Y ReutherA S Baldwin
Aug 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·Siddhartha JaiswalIrving L Weissman
Oct 8, 2003·Current Cancer Drug Targets·Luke WhitesellRyan Falsey
Jan 28, 2004·Cell·Nika N Danial, Stanley J Korsmeyer
Jan 28, 2004·Cancer Research·Nicholas J DonatoShishir Shishodin
Feb 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·M Golam MohiBenjamin G Neel
Feb 26, 2004·Blood·Bruno Calabretta, Danilo Perrotti
May 22, 2004·Cell Cycle·Ralph K LindemannRicky W Johnstone
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Jul 24, 2004·Hematology/oncology Clinics of North America·Junia V Melo, Michael W N Deininger
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Purva BaliKapil Bhalla
Aug 26, 2004·Advances in Cancer Research·Brian J Druker
Oct 16, 2004·Proceedings of the National Academy of Sciences of the United States of America·Hisashi HaradaStanley J Korsmeyer
Jan 29, 2005·Proceedings of the National Academy of Sciences of the United States of America·Kiranmai GumireddyE Premkumar Reddy
Feb 12, 2005·Proceedings of the National Academy of Sciences of the United States of America·Michael R BurgessCharles L Sawyers
Feb 16, 2005·Cancer Cell·Thomas O'HareBrian J Druker
Feb 16, 2005·Cancer Cell·Ellen WeisbergJames D Griffin
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kapil N Bhalla
Jul 1, 2005·Nature·Franziska MichorMartin A Nowak
Jul 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mirna GolemovicMiloslav Beran
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingRoss L Levine

❮ Previous
Next ❯

Citations

Dec 4, 2010·Investigational New Drugs·Sridurga MithraprabhuAndrew Spencer
Apr 29, 2010·Current Hematologic Malignancy Reports·G Vignir HelgasonTessa L Holyoake
Feb 18, 2011·Current Hematologic Malignancy Reports·Fabio P S Santos, Alfonso Quintás-Cardama
Mar 12, 2013·International Journal of Hematology·Teru Hideshima, Kenneth C Anderson
Sep 9, 2011·Molecular Pharmaceutics·Robert W RobeySusan E Bates
Nov 29, 2007·Current Opinion in Oncology·Dragana Milojkovic, Jane Apperley
May 4, 2007·The Cancer Journal·Susan E Bates, Richard L Piekarz
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Warren FiskusKapil Bhalla
Apr 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tri NguyenSteven Grant
Oct 7, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Warren FiskusKapil N Bhalla
Dec 17, 2008·Hematology·Junia V Melo, Charles Chuah
Aug 10, 2010·Core Evidence·Elias JabbourHagop Kantarjian
May 11, 2011·Cancer Management and Research·David L DeremerCelalettin Ustun
Nov 19, 2009·Drug Design, Development and Therapy·Carmen FavaElias Jabbour
Jul 3, 2008·World Journal of Gastroenterology : WJG·Martin HaefnerMarcus Wiedmann
Feb 25, 2011·Future Oncology·Paula Garland, Jane Apperley
Feb 28, 2007·Leukemia & Lymphoma·Sucha Nand, Kevin Barton
Sep 2, 2008·Expert Review of Anticancer Therapy·Ruriko Tanaka, Shinya Kimura
Oct 20, 2007·Expert Review of Anticancer Therapy·Mark BishtonH Miles Prince
May 22, 2008·Expert Opinion on Investigational Drugs·Thomas O'HareMichael W Deininger
Jun 10, 2008·Expert Opinion on Emerging Drugs·Dominik Sebastian MestelWolfram Sterry
Mar 1, 2011·Expert Opinion on Emerging Drugs·Aine Carol BurkeFrancis J Giles
Apr 28, 2007·Expert Opinion on Investigational Drugs·Walid K RasheedH Miles Prince
Apr 29, 2014·Pharmacology & Therapeutics·Prithviraj BoseSteven Grant
Jan 15, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Masanobu TsubakiShozo Nishida
Aug 22, 2012·Cancer Letters·Leslie A Crews, Catriona H M Jamieson
Sep 27, 2012·Hematology/oncology Clinics of North America·Warren FiskusKapil N Bhalla
Jul 28, 2011·Taiwanese Journal of Obstetrics & Gynecology·Yen-Ying MaChia-Chi Lung
Sep 30, 2010·Seminars in Hematology·Alfonso Quintás-CardamaJorge Cortes
Dec 17, 2009·Clinical Lymphoma & Myeloma·Alfonso Quintás-Cardama, Jorge E Cortés

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis